AndroScience Lands $4,000,000 Series C Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    11175 Flintkote Avenue San Diego, CA 92121
  • Company Description
    AndroScience has recently discovered and patented a family of compounds derived from natural products that enhance the degradation of androgen receptor protein. These compounds selectively enhance androgen receptor degradation and do not affect endogenous androgens (testosterone or dihydrotestosterone). To our knowledge, this is a novel and unique mechanism of action and no other companies have compounds with a similar mechanism of action. These compounds appear efficacious both topically and systemically and could be good candidates for acne, alopecia, prostate cancer, benign prostatic hyperplasia (BPH), and other androgen related diseases.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor

Trending on Xconomy